Piramal Pharma

Piramal has committed to reducing absolute scope 1 and 2 GHG emissions by 42 per cent by FY2030 from an FY2022 base year. It has…

Just a day before the union budget 2024-25 announcement, experts in pharma sector are united in their call for regulatory reforms,…

Revenue from operation grew by 11 per cent to Rs 3,202 crore versus Rs 2,889 crore in H1FY22

Piramal Pharma includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO);…

The report articulates PPL’s ESG strategic and operational framework, and execution roadmap, including specific objective targets

The Mumbai-based company has acquired a 27.78 per cent stake in Yapan as a result of the investment

The company plans to create two separate listed entities in financial services and pharmaceuticals

In March this year, Piramal Pharma entered into an agreement to acquire a 100 per cent stake in Hemmo Pharmaceuticals for an…

This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs

This deal will increase Piramal Pharma’s stake to 100 per cent in Convergence Chemicals